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When the first cases of AIDS appeared and the news 
about the nature of the new disease spread the 
developed world was stunned. This could not have been 
the consequence of the fact that the new disease caused 
people to be sick and die: people have been sick and 
were dying from many other causes ranging from war 
to traffic accidents and from pollution to influenza. 
Nor could it have been because the victims were so 
numerous - there were many other causes of death 
and disease affecting many times the numbers of people 
affected by AIDS. Malaria alone counted its victims 
in hundreds of millions and suicide would kill at least 
a 100,000 people in Europe each year. Nor could it have 
been because of the bad way in which people were ailing 
and losing hope - there were so many other manners 
in which people or nature have been making humans 
suffer and lose dignity or die. Numerous other reasons 
for the world's reaction were clearly at play ranging 
from the ethical issues arising in dealing with AIDS 
to the forbidden ways in which the illness was 
contracted. Among these reasons there was one which 
was particularly important: AIDS was a disease which 
has shattered our confidence and interrupted the series 
of our victories over nature, over insects, over disease 
and even over death. 
In the seventh decade of this century everything 
seemed within reach given a little more good will, a 
little more time, a little more money. Traffic accidents 
were cruel life-takers but we had found methods to 
prevent their occurrence by building better roads, 
driving better cars and drinking a little less while doing 
so. New surgery dealt painlessly with a variety of 
previously lethal afflictions. Pollution was clearly 
controllable by legislation whenever governments and 
individuals became serious about it. Even neuro-
psychiatry disorders proved to be amenable to primary 
prevention and effective treatment in a large proportion 
of cases.1 
AIDS came as a blow to this confident and optimist, 
technologically perfect, almost brave new world: a 
communicable disease was at large, impervious to all 
known treatment, spreading inexorably and killing in 
ugly and undignified ways. The behavioural changes 
which seemed to be necessary to prevent its spread were 
different from those involved in reducing skiing 
accidents. Nothing seemed to work as it should and 
a series of predictable reactions followed. New 
treatments were promoted without credible evidence 
about their effectiveness. Individuals, nations and 
certain professions were declared culprits and found 
themselves scapegoated in a violent way. Lies and 
alarming news emerged with ease and could not be 
fought effectively. Soon after the world admitted that 
the disease exists it became unusually easy to find 
resources for research clearly expressing a hope that 
the magic of science will wipe out the disease which 
may be a harbinger of many other threats to society's 
progress. 
The developing countries reacted differently. The 
third world suffers from innumerable ills and diseases: 
one more, no matter how lethal or invasive, can be more 
easily overlooked in the host of those sapping the 
strength of the nation and making the life of individuals 
and communities a high risk proposition throughout 
its duration. Gradually however the attitude changed: 
HIV infections became recognized as a new problem, 
governments reacted, money and other resources from 
inside and outside found their users. 
Thus, by the mid-1980s the world was mobilized. 
While myths still abounded, ignorance blocked progress 
and many obstacles of a moral, traditional and 
economic nature barred the way, nevertheless attitudes 
and responses were beginning to change. Figures 
coming in from all corners of the world were 
frightening. Problems accompanying the disease were 
clearly serious, numerous and growing. Initial concerns 
were focussed on physical aspects of the ailment and 
on research needs. Gradually the focus shifted towards 
societal and economic aspects of the infection. The 
psychosocial and neuropsychiatric problems and the 
necessity to do something about them were recognised 
much more slowly and resources to deal with them were 
much more difficult to find. This is still so in many 
countries and even internationally: but there seem to 
be signs that priorities might shift to include these 
conditions as well. 
Psychosocial and behavioural problems related to the 
HIV infection can contribute to its spread and 
complicate its course and management. Abuse of drugs 
and high risk behaviours are among the most important 
reasons for the spread of the illness. Dementia and 
other grave syndromes related to brain damage and to 
diseases complicating AIDS are a public health problem 
of vast proportions. Reactive depression and other 
mental disorders complicate management. Burn-out in 
staff and relatives renders health service tasks more and 
more difficult. 
There are various ways in which these problems can 
be grouped: perhaps the simplest is to think about them 
as those being experienced by the infected individuals, 
those experienced by others who look after them and 
those which society as a whole has to face. The 
distinction however is not easy to maintain and the three 
groups of problems intertwine and affect each other's 
magnitude and nature. Depression in a relative affects 
the course of disease in the infected person and a change 
of societies' - or communities' - attitudes to the 
disease affects the quality of life and medical outcomes 
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of diseases. Nevertheless, the division into these three 
groups is possible and sometimes useful when 
intervention strategies are examined. 
(1) The problems for affected individuals 
Neuropsychiatric and psychosocial problems in 
infected individuals are numerous, often grave and 
difficult to handle. In part this is because they 
emerge burdened with stigmas of mental illness, 
sin and fatality; in part because they are not well 
understood. It is as yet unclear which of the neuro-
psychiatric and psychosocial disorders occurring 
in the infected individuals can be directly and 
causally linked to the presence of the virus in the 
brain and to the neuropathological changes which 
can be found on post mortem examinations, and 
which are psychological reactions to the illness or 
to the inevitability of imminent death. The certainty 
of the causal connection diminishes with the 
diminishing severity of disorders: mild cognitive 
disorders for example described with considerable 
frequency in HIV infected individuals could be due 
to organic causes, to psychosocial reactions to the 
multiple stresses to which HIV positive individuals 
are exposed, to the complex relationships between 
exhaustion and cognitive function or to a com-
bination of all those. Suicide and some of the 
affective disorders are more frequent in HIV 
positive individuals but it is also quite frequent -
and more frequent than in the rest of the 
population - in the groups which are at high risk 
for AIDS. Research and service interventions are 
also blocked by the curse of Babel: clinical 
descriptions and neuropsychiatric and psychosocial 
problems occurring in HIV infection are imprecise, 
and instruments still used for their assessment are 
of doubtful validity and reliability. 
To break the vicious circle of misunderstanding 
and render research and service easier the World 
Health Organisation (WHO) has brought together 
groups of leading specialists and produced together 
with them definitions for all the neuropsychiatric 
and some of the psychosocial disorders occurring 
in HIV infection.2 It has also undertaken a major 
international study in a variety of cultures aiming 
to produce instruments for the assessment of 
mental and neurological functioning in HIV 
infected individuals and to validate these 
instruments.3 
In both of these efforts the results have until now 
been most encouraging: we were able to 
demonstrate that it is possible to create a system 
of assessment and diagnosis which is internally 
consistent, congruent with the International 
Classification of Diseases (WHO, 1992)4 accept-
able to scientists in the different disciplines 
concerned and applicable in different cultures. The 
instruments will be released soon and it is to be 
hoped that they will be used in research and in 
clinical practice the world over: a common language 
is undoubtedly a first prerequisite for communi-
cation, sharing of data and collaboration.5 
Such collaboration will not only help in de-
veloping the knowledge necessary for the conduct 
of effective programmes concerned with the benefit 
of patients suffering from AIDS: it is highly likely 
that the assessment tools - for example the 
neurocognitive tests - and the insights gained in 
studies of the relationship between demonstrable 
brain damage and psychological functioning in 
HIV infection will help the development of 
behavioural science and of psychiatry in general. 
The WHO multicentric study3 also aims to 
obtain data about the frequency and form which 
neuropsychiatric and psychosocial problems related 
to HIV infections in different cultures can have. 
The detailed assessment of some 1200 individuals 
- including carefully matched groups of HIV 
negative, seropositive but clinically asymptomatic, 
and seropositive individuals with symptoms -
should provide firm evidence about the nature of 
these disorders in different cultures: a follow-up 
study over three years will produce data about the 
longitudinal development of the condition and 
create a network of centres in different parts of the 
world, all using the same methods and sharing 
experience and resources. 
Dependence on the abuse of alcohol and other 
drugs are among the main risk factors for the 
infection and complicate its course. Here the 
Organization took a slightly different tack: it 
concentrated on the exploration of evidence about 
the frequency of different types of drug abuse and 
on the assessment of treatment or prevention 
strategies which could diminish the danger of HIV 
infection even if the drug abuse problem proves to 
be resistant to interventions. The definition of 
methods for changing drug abuse related behaviour 
is just as much a problem here as it is in relation 
to other high risk ways of living. 
(2) The problems facing carers 
The second group of problems arise in those who 
are close to people with AIDS or look after them 
professionally. The burn out syndrome occurring 
with an increasing frequency in various occupations 
in the field of health has already been called a 
major epidemic in its own right. Its causes are 
many, ranging from low salary and repetitive work 
to the frequent failure to see recovery in a patient, 
the constant need to deal with stigma and the 
feeling of danger to oneself. Many of these features 
are present in the instance of AIDS and a number 
of reports speak of the refusal to continue working 
with AIDS patients, of excessive fatigue, minor 
psychiatric problems and the appearance of burn-
out syndrome in many services. Epidemiological 
assessments of these problems are still lacking and 
numerous methodological difficulties are likely to 
make the interpretation of data of future studies 
difficult: nevertheless it is high time to carry them 
out, linking them wherever possible with inter-
vention programmes. 
Members of families of those affected suffer 
from a multitude of problems and need help. Much 
of this is material support: the role of moral and 
psychological support however is crucial and 
unfortunately widely neglected. The World Health 
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Organization has so far concentrated on the production 
of guidelines about counselling, the organization of 
relevant services and ways to diminish stigma and 
prejudice - at community and at individual level -
directed against HIV infected individuals and those who 
surround them.6 While the technology has thus be-
come available its application - with the exception of 
a few settings - is lagging behind and needs a major 
organizational and motivational push if progress is to 
be achieved. 
(3) The problems for society 
The third group of problems is at the doorstep of 
society: there is at present still much to do to create 
appropriate legal bases enabling health services to 
perform their duty well. There is also the urgent 
need to produce realistic options for the care for 
the large numbers of individuals who will be 
affected by neuropsychiatric problems related to the 
HIV infections - from the most severe such as 
dementia to the more insidious ones such as the 
various mood disorders. WHO has recently pro-
duced its first estimates of the numbers of 
individuals likely to be affected by these problems 
and it is clear that the current already insufficient 
health care provisions for the mentally ill will 
become so overtaxed that they will fail in their 
mandate. WHO has developed strategies of mental 
health care which could be used to help countries 
in this respect: but the determination to start 
programmes must come from the countries them-
selves. Care for people affected by a neuro-
psychiatric problem related to HIV will have to face 
the unprecedented triple challenge of stigma 
attached to mental illness, of stigma and fear 
attached to AIDS and of the lack of effective 
treatment methods: a triple challenge which must 
be faced now. 
Also at the door of society lies the need to deal 
with numerous ethical issues and solve problems 
related to massive behaviour change. These 
challenges relate to changing sexual behaviour, to 
reducing drug abuse, to educational efforts which 
could increase tolerance to disease and disability, 
to appropriate information spread and to numerous 
other issues affecting the spread of AIDS and living 
in a community of people or nations in general. 
So far WHO has concentrated on the provision of 
sound information about techniques available for 
work in this field and has collaborated with 
countries in the framework of national AIDS 
programmes.7
 Much more however will have to be 
done both by the Organization and by its member 
states if progress which seems to have been 
occurring is to be maintained. 
Cutting across these three groups of problems are 
research needs. WHO, having consulted leading experts 
and institutions, produced a series of recommendations 
about future investigations. These are many: the most 
pertinent however relate to the need to establish - in 
as many countries as possible - the research infra-
structure which will allow a concerted and lasting 
programme of collaborative studies involving scientists 
from different disciplines and working in different 
settings, worldwide. Specific recommendations deal 
with research on the effectiveness of treatment, with 
the evaluation of policy alternatives, with further 
basic neuroscience studies and with crosscultural 
differences in the expression of symptoms and in their 
assessment. 
Until now WHO has served as the public health 
platform on which researchers, clinicians and health 
decision makers could meet to exchange experience and 
agree on action. A public health platform however is 
never neutral: it is biasing debates towards action which 
will benefit the largest possible number of people in 
the shortest possible time and at the lowest price. There 
may be no other instance in which such a platform can 
be as useful as in the instance of dealing with 
neuropsychiatric and psychosocial problems related to 
HIV infection and AIDS. 
A platform however can not be useful if it has not 
attracted outstanding people of good will armed with 
knowledge and willing to work together. This editorial 
is written in the hope that this will happen and that 
such people will take an active part in the global fight 
against misery caused by neuropsychiatric problems 
related to HIV infection. WHO's programmes provide 
one opportunity to do so: there are however numerous 
other occasions in research, training, teaching or health 
education. 
Norman Sartorius, 
MD, MA, DPM, PhD, FRCPsych, 
Director 
Division of Mental Health, World Health Organisation, 
CH-1211 Geneva 27, Switzerland. 
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